New Insights into the Use of Empagliflozin—A Comprehensive Review
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10123294
Abstract: Empagliflozin is a relatively new drug that, as an inhibitor of the sodium–glucose cotransporter 2 (SGLT2), causes increased urinary glucose excretion and thus contributes to improved glycemic control, better glucose metabolism, reduced glucotoxicity and insulin… read more here.
Keywords: use empagliflozin; empagliflozin; empagliflozin comprehensive; drug ... See more keywords